Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956 · View on ClinicalTrials.gov ↗

Study Summary

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

Interventions

  • OTHER Non-Interventional Study

Study Locations (20)

Other

  • Medical University of Vienna — Vienna
  • AC Camargo Cancer Center — São Paulo
  • Institut Universitaire du Cancer Toulouse Oncopole — Toulouse
  • University Hospital Essen — Essen
  • Meir Medical Center, Faculty of Medicine - Tel-Aviv University — Kefar Sava
  • Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale — Naples
  • Hospital Materno Infantil Las Palmas — Las Palmas
  • Hospital Universitario La Paz — Madrid
  • Ospedale Regionale di Lugano, Civico — Lugano

MI

  • Fondazione IRCCS Istituto Nazionale Tumori — Milan
  • European Institute of Oncology — Milan

Minnesota

  • Mayo Clinic in Rochester — Rochester

New York

  • Memorial Sloan Kettering Cancer Center — New York

Texas

  • Houston Methodist Hospital — Houston

Ontario

  • Sunnybrook Health Sciences, University of Toronto — Toronto

Quebec

  • Hopital Maisonneuve Rosemont — Montreal

CN

  • Ospedale Michele e Pietro Ferrero — Verduno

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2024-12-04
Est. Completion 2029-10-31

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06689956

The ClinicalTrials.gov registry entry for NCT06689956 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention — of which Non-Interventional Study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06689956 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, MI, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06689956 about?

NCT06689956 is a clinical study titled "Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study". This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

What is the current status of trial NCT06689956?

This trial is currently recruiting. The enrollment target is 212 participants. The study started on 2024-12-04. Estimated completion is 2029-10-31.

What conditions does trial NCT06689956 study?

This clinical trial studies the following conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06689956?

The interventions under investigation include: Non-Interventional Study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06689956?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06689956 being conducted?

This trial has 20 study locations across Minnesota, New York, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial